Re-irradiation With Carbon Ion Radiotherapy for Pelvic Rectal Cancer Recurrences in Patients Previously Irradiated to the Pelvis.
Adult
Aged
Female
Follow-Up Studies
Heavy Ion Radiotherapy
/ adverse effects
Humans
Kaplan-Meier Estimate
Magnetic Resonance Imaging
Male
Middle Aged
Neoplasm Recurrence, Local
Pelvis
/ diagnostic imaging
Prognosis
Re-Irradiation
Rectal Neoplasms
/ diagnostic imaging
Tomography, X-Ray Computed
Treatment Outcome
Rectal cancer recurrence
carbon ion radiotherapy
re-irradiation
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
09
03
2020
revised:
20
03
2020
accepted:
24
03
2020
entrez:
2
5
2020
pubmed:
2
5
2020
medline:
11
2
2021
Statut:
ppublish
Résumé
Re-irradiation of locally recurrent rectal cancer poses challenges due to the proximity of critical organs, such as the bowel. This study aimed at evaluating the safety and efficacy of re-irradiation with Carbon Ion Radiotherapy (CIRT) in rectal cancer patients with local recurrence. Between 2014 and 2018, 14 patients were treated at the National Center of Oncological Hadrontherapy (CNAO Foundation) with CIRT for locally recurrent rectal cancer. All patients concluded the treatment. No G≥3 acute/late reaction nor pelvic infections were observed. The 1-year and 2-year local control rates were, 78% and 52%, respectively, and relapse occurred close to the bowel in 6 patients. The 1-year and 2-year overall survival rates were 100% and 76.2% each; while the 1-year and 2-year metastasis free survival rates were 64.3% and 43%. CIRT as re-irradiation for locally recurrent rectal cancer emerges as a safe and valid treatment with an acceptable rate of morbidity of surrounding healthy tissue.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Re-irradiation of locally recurrent rectal cancer poses challenges due to the proximity of critical organs, such as the bowel. This study aimed at evaluating the safety and efficacy of re-irradiation with Carbon Ion Radiotherapy (CIRT) in rectal cancer patients with local recurrence.
PATIENTS AND METHODS
METHODS
Between 2014 and 2018, 14 patients were treated at the National Center of Oncological Hadrontherapy (CNAO Foundation) with CIRT for locally recurrent rectal cancer.
RESULTS
RESULTS
All patients concluded the treatment. No G≥3 acute/late reaction nor pelvic infections were observed. The 1-year and 2-year local control rates were, 78% and 52%, respectively, and relapse occurred close to the bowel in 6 patients. The 1-year and 2-year overall survival rates were 100% and 76.2% each; while the 1-year and 2-year metastasis free survival rates were 64.3% and 43%.
CONCLUSION
CONCLUSIONS
CIRT as re-irradiation for locally recurrent rectal cancer emerges as a safe and valid treatment with an acceptable rate of morbidity of surrounding healthy tissue.
Identifiants
pubmed: 32354961
pii: 34/3/1547
doi: 10.21873/invivo.11944
pmc: PMC7279804
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1547-1553Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Radiat Oncol. 2015 Feb 28;10:57
pubmed: 25889149
Ann Surg Oncol. 2015;22(6):2068-74
pubmed: 25384705
Med Phys. 2015 Jan;42(1):263-75
pubmed: 25563266
Technol Cancer Res Treat. 2014 Aug;13(4):303-14
pubmed: 24206209
In Vivo. 2019 Mar-Apr;33(2):473-476
pubmed: 30804128
Anticancer Res. 2019 Sep;39(9):4613-4617
pubmed: 31519558
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv263
pubmed: 29741565
Phys Med Biol. 2000 Nov;45(11):3319-30
pubmed: 11098906
N Engl J Med. 2004 Oct 21;351(17):1731-40
pubmed: 15496622
Radiother Oncol. 2017 Jan;122(1):146-151
pubmed: 28057329
Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1129-39
pubmed: 16414206
BMC Cancer. 2012 Apr 03;12:137
pubmed: 22472035
Ann Oncol. 2013 Oct;24 Suppl 6:vi81-8
pubmed: 24078665
Med Phys. 2018 May;45(5):2266-2277
pubmed: 29537642
Curr Oncol. 2018 Dec;25(6):378-383
pubmed: 30607112
Phys Med Biol. 2013 Jun 7;58(11):3837-47
pubmed: 23681116
World J Gastroenterol. 2016 Jan 28;22(4):1721-6
pubmed: 26819536
Radiother Oncol. 2016 Aug;120(2):307-12
pubmed: 27394694
Adv Health Sci Educ Theory Pract. 2010 Oct;15(4):491-516
pubmed: 20069357
Br J Radiol. 2012 Mar;85(1011):259-64
pubmed: 21385917
Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):93-101
pubmed: 27375166
World J Surg Oncol. 2016 Oct 12;14(1):262
pubmed: 27733205
Lancet. 2009 Mar 7;373(9666):811-20
pubmed: 19269519
Phys Med. 2015 Jun;31(4):333-51
pubmed: 25840619
Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):1175-80
pubmed: 18207667
Int J Cancer. 2019 Jun 15;144(12):2992-3000
pubmed: 30536395
Phys Med Biol. 2012 Nov 21;57(22):7543-54
pubmed: 23104051
Nat Rev Clin Oncol. 2010 Jan;7(1):37-43
pubmed: 19949433